000597.SHE Northeast Pharmaceutical Group Co Ltd
- Market cap
- CNY 6.19B
- P/E
- 33.4x
- P/B
- 1.12x
- ROE
- 2.5%
- Dividend yield
- 3.18%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000597.SHE undervalued?
Graham number000597.SHE trades 28.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Northeast Pharmaceutical Group Co Ltd fundamental analysis
No fundamental analysis for Northeast Pharmaceutical Group Co Ltd yet.
Northeast Pharmaceutical Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Northeast Pharmaceutical Group Co Ltd
Northeast Pharmaceutical Group Co., Ltd. engages in chemical pharmaceuticals manufacturing, pharmaceutical distribution, pharmaceutical engineering, biopharmaceuticals, and other businesses in China. It offers vitamin products, such as vitamin C, vitamin B1, vitamin B6, and L-carnitine series; anti- infective products, such as fosfomycin series, azithromycin series, amantadine series, polyalkali hydrochloride, chloramphenicol, and other products; and reproductive system and …
Full company profileNortheast Pharmaceutical Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Northeast Pharmaceutical Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 4.81B | 5.68B | 7.47B | 8.22B | 7.38B | 8.15B | 8.81B | 8.24B | 7.50B | 7.07B | 6.47B |
| Gross Profit | 1.42B | 2.17B | 3.00B | 3.45B | 2.79B | 3.09B | 3.25B | 3.12B | 2.76B | 2.64B | 2.09B |
| Operating Income | 1.60M | 115M | 76.0M | 210M | 153M | 187M | 696M | 498M | 578M | 499M | 341M |
| EBITDA | 440M | 656M | 498M | 630M | 694M | 722M | 754M | 911M | 1.02B | 897M | 222M |
| Net Income | 23.8M | 119M | 195M | 174M | 12.3M | 99.0M | 350M | 358M | 410M | 260M | 136M |
| EPS | 0.02 | 0.11 | 0.16 | 0.14 | 0.01 | 0.07 | 0.26 | 0.25 | 0.29 | 0.18 | 0.10 |
| Balance Sheet | |||||||||||
| Total Assets | 9.79B | 10.6B | 11.7B | 12.5B | 12.2B | 13.2B | 13.8B | 15.3B | 14.4B | 12.9B | 13.1B |
| Total Liabilities | 7.36B | 8.05B | 8.13B | 8.62B | 8.04B | 8.89B | 9.10B | 10.1B | 8.88B | 7.22B | 7.44B |
| Shareholders' Equity | 2.31B | 2.43B | 3.47B | 3.81B | 3.98B | 4.14B | 4.56B | 4.99B | 5.32B | 5.53B | 5.55B |
| Cash & Short-term Investments | 2.14B | 1.71B | 1.28B | 1.53B | 1.48B | 2.55B | 3.84B | 5.65B | 4.47B | 3.60B | 4.22B |
| Total Debt | 4.11B | 3.82B | 3.05B | 3.03B | 3.51B | 3.40B | 2.14B | 2.18B | 1.57B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 385M | -301M | 285M | 353M | 571M | 747M | 1.11B | 587M | 759M | 1.11B | - |
| Capital Expenditure | 177M | 415M | 566M | 229M | 400M | 120M | 244M | 235M | 159M | 97.8M | 61.4M |
| Free Cash Flow | 208M | -716M | -281M | 123M | 171M | 627M | 864M | 351M | 599M | 1.01B | 192M |
| Ratios | |||||||||||
| ROE | 1.0% | 4.9% | 5.6% | 4.6% | 0.3% | 2.4% | 7.7% | 7.2% | 7.7% | 4.7% | 2.5% |
| ROA | 0.2% | 1.1% | 1.7% | 1.4% | 0.1% | 0.8% | 2.5% | 2.3% | 2.8% | 2.0% | 1.0% |
| Net Profit Margin | 0.5% | 2.1% | 2.6% | 2.1% | 0.2% | 1.2% | 4.0% | 4.3% | 5.5% | 3.7% | 2.1% |
| Debt to Equity | 1.77x | 1.57x | 0.88x | 0.79x | 0.88x | 0.82x | 0.47x | 0.44x | 0.30x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Northeast Pharmaceutical Group Co Ltd dividends
- Dividend yield
- 3.18%
- Forward dividend
- 0.06 CNY
- Payout ratio
- 75.7%
- Ex-dividend date
- Jun 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 197M | 0.14 | 75.7% |
| 2024 | CNY 206M | 0.14 | 50.3% |
| 2023 | CNY 220M | 0.15 | 61.3% |
| 2022 | CNY 18.9M | 0.01 | 5.4% |
| 2021 | CNY 10.8M | 0.01 | 10.9% |
| 2020 | CNY 125M | 0.10 | 1,019.5% |
| 2019 | CNY 136M | 0.11 | 77.9% |
| 2018 | CNY 167M | 0.14 | 85.3% |
| 2017 | CNY 159M | 0.15 | 133.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.49:1 on May 20, 2020.
Who owns Northeast Pharmaceutical Group Co Ltd
- Insiders 60.91%
- Institutions 1.23%
- Public & others 37.86%
- Shares outstanding 1.43B
- Free float 599M
Northeast Pharmaceutical Group Co Ltd company profile
- Company name
- Northeast Pharmaceutical Group Co Ltd
- Ticker
- 000597.SHE
- ISIN
- CNE0000009G0
- Exchange
- Shenzhen Stock Exchange
- Listed since
- May 9, 1996
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5,727
- Fiscal year end
- December
- Address
- No. 8, Kunming Street, Shenyang, China, 110027
- Phone
- 86 24 2580 6963
- Website
- nepharm.com.cn
About Northeast Pharmaceutical Group Co Ltd
Northeast Pharmaceutical Group Co., Ltd. engages in chemical pharmaceuticals manufacturing, pharmaceutical distribution, pharmaceutical engineering, biopharmaceuticals, and other businesses in China. It offers vitamin products, such as vitamin C, vitamin B1, vitamin B6, and L-carnitine series; anti- infective products, such as fosfomycin series, azithromycin series, amantadine series, polyalkali hydrochloride, chloramphenicol, and other products; and reproductive system and hormone products comprising carboprost suppositories, carboprost tromethamine, dapoxetine hydrochloride, and levonorgestrel and tadalafil tablets. It also provides nervous system products, such as piracetam series, levetiracetam series, vinpocetine, and other products; narcotics and psychotropic drugs and related products, including morphine hydrochloride injections and tablets, oxycodone hydrochloride injection, compound glycyrrhiza series, and acetaminophen-codeine tablets; anti-AIDS products comprising Krughar /zidovudine tablets and capsules, efavirenz tablets, and other products; and in vitro biological diagnostic reagent products for HIV, HBV, HCV, HPV, and TB. In addition, it offers general health products, including glucosamine sulfate chondroitin collagen D3 calcium capsules, protein powder, probiotic powder, effervescent tablets, chewable tablets, solid drinks, and other products. Further, it provides Enterogermina, magnesium aluminum carbonate chewable tablets; compound proglutamine-cimetidine tablets; acetaminophen tablets; pain relievers, phenacetin, pregabalin, noscapine syrup, and citrate table; and other products, as well as cell therapy products. Additionally, it engages in medical distribution business. The company was founded in 1946 and is based in Shenyang, China.
Northeast Pharmaceutical Group Co Ltd management
2- Mr. Yonggang CaiGM & Director · born 1980
- Ms. Xin LiChief Financial Officer · born 1980